Published in Mol Brain on November 03, 2016
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science (1992) 11.83
B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 11.53
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol (2003) 6.32
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci (2011) 5.64
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
Oxidative stress and neurodegeneration: where are we now? J Neurochem (2006) 5.44
Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature (2012) 4.95
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci (2008) 4.64
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (2004) 4.09
Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A (2006) 3.98
Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem (1996) 3.84
Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci (2010) 3.81
Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem (2011) 3.57
Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol (1992) 3.53
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem (1993) 3.52
Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant (2011) 3.49
Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med (2014) 3.45
Mapping protein post-translational modifications with mass spectrometry. Nat Methods (2007) 3.44
Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 3.39
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging (2005) 3.32
Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology (2007) 3.26
Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol (1999) 3.20
Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci (1997) 3.08
The pathobiology of vascular dementia. Neuron (2013) 3.07
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2005) 2.97
Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol (1996) 2.95
Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J (2005) 2.91
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med (2001) 2.63
Oxidatively modified proteins in aging and disease. Free Radic Biol Med (2002) 2.51
Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem (2004) 2.46
Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev (2013) 2.46
Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int (2006) 2.44
Neurodegenerative diseases and oxidative stress. Biomed Pharmacother (2004) 2.44
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis (2011) 2.32
Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol (2007) 2.31
The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol (2010) 2.31
The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging (2000) 2.30
The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet (2000) 2.24
Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol (2005) 2.20
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med (2002) 2.10
Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.09
Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med (2007) 2.08
Peroxynitrite reactivity with amino acids and proteins. Amino Acids (2003) 2.06
The epidemiology of the dementias: an update. Curr Opin Psychiatry (2007) 2.05
Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. Mol Cell Proteomics (2012) 2.04
Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics (2010) 1.97
Biomarkers in Alzheimer's disease drug development. Alzheimers Dement (2011) 1.97
Inhibition of mitochondrial electron transport by peroxynitrite. Arch Biochem Biophys (1994) 1.94
Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging (1988) 1.89
What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett (1997) 1.87
Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett (1996) 1.87
Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging (2002) 1.86
Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol (2008) 1.86
Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem (1995) 1.84
Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology (2000) 1.76
Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. Proc Natl Acad Sci U S A (1997) 1.75
RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A (2009) 1.74
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem (2002) 1.73
Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem (2003) 1.70
Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol (2012) 1.65
Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain (2013) 1.64
Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol (2010) 1.59
Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis (2005) 1.58
Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol (2012) 1.57
Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int (2011) 1.56
Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J Biol Chem (1991) 1.54
Deamidation of human proteins. Proc Natl Acad Sci U S A (2001) 1.53
Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging (2005) 1.52
Proteolytic degradation of tyrosine nitrated proteins. Arch Biochem Biophys (2000) 1.49
Twenty years of Alzheimer's disease-causing mutations. J Neurochem (2011) 1.49
Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol (1990) 1.48
Pyramidal neurons of the prefrontal cortex in post-stroke, vascular and other ageing-related dementias. Brain (2014) 1.45
Protein deamidation. Proc Natl Acad Sci U S A (2002) 1.44
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem (2005) 1.42
Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron (2011) 1.42
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
Chaperones, protein aggregation, and brain protection from hypoxic/ischemic injury. J Exp Biol (2004) 1.39
The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. Arch Gen Psychiatry (1997) 1.38
Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol (2012) 1.37
Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology (2011) 1.37
Prediction of protein deamidation rates from primary and three-dimensional structure. Proc Natl Acad Sci U S A (2001) 1.36